Compile Data Set for Download or QSAR
Report error Found 151 Enz. Inhib. hit(s) with all data for entry = 11449
TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617046(US11752155, Compound E1-38.6B')
Affinity DataKi:  0.110nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617044(US11752155, Compound E1-38.2B')
Affinity DataKi:  0.180nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617051(US11752155, Compound III-E1-38.1B')
Affinity DataKi:  0.290nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617045(US11752155, Compound E1-38.4B')
Affinity DataKi:  0.350nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataKi:  0.413nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617024(US11752155, Compound E1-22.5B')
Affinity DataKi:  0.490nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataKi:  0.716nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617047(US11752155, Compound E1-38.8B')
Affinity DataKi:  0.800nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617030(US11752155, Compound E1-22.3B')
Affinity DataKi:  0.810nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287603(BDBM617007 | US9567341, Compound C-179 | BDBM41361...)
Affinity DataKi:  0.838nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617032(US11752155, Compound E1-22.6B')
Affinity DataKi:  0.940nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388303(US10294230, Compound E1-21.26 | US10584127, Compou...)
Affinity DataKi:  1.02nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617055(US11752155, Compound E2-38.2B')
Affinity DataKi:  1.10nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617031(US11752155, Compound E1-22.4B')
Affinity DataKi:  1.10nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617026(US11752155, Compound E1-21.4B')
Affinity DataKi:  1.30nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617034(US11752155, Compound E1-23.2B')
Affinity DataKi:  1.30nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435146(US10584127, Compound E1-8.2 | US11136328, Compound...)
Affinity DataKi:  1.40nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM287602(US9567341, Compound C-178 | US9968610, Compound C-...)
Affinity DataKi:  1.42nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617049(US11752155, Compound III-E1-22.1B')
Affinity DataKi:  1.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617033(US11752155, Compound E1-22.28B')
Affinity DataKi:  1.60nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617038(US11752155, Compound E1-24.2B')
Affinity DataKi:  2.10nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617041(US11752155, Compound E1-37.2B')
Affinity DataKi:  2.40nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617021(US11752155, Compound E1-1.5B')
Affinity DataKi:  2.55nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617025(US11752155, Compound E1-22.30B')
Affinity DataKi:  2.60nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617050(US11752155, Compound III-E1-37.1B')
Affinity DataKi:  2.90nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617022(US11752155, Compound E1-22.26B')
Affinity DataKi:  3.40nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617048(US11752155, Compound E1-38.10B')
Affinity DataKi:  3.80nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617043(US11752155, Compound E1-37.6B')
Affinity DataKi:  3.90nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617040(US11752155, Compound E1-24.6B')
Affinity DataKi:  4.70nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617042(US11752155, Compound E1-37.4B')
Affinity DataKi:  4.70nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388294(US10294230, Compound E1-1.2 | US10584127, Compound...)
Affinity DataKi:  4.81nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617037(US11752155, Compound E1-23.26B')
Affinity DataKi:  6.5nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617036(US11752155, Compound E1-23.4B')
Affinity DataKi:  7.80nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388299(US10294230, Compound E1-1.3 | US10584127, Compound...)
Affinity DataKi:  8.67nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617021(US11752155, Compound E1-1.5B')
Affinity DataIC50: 9.60nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617021(US11752155, Compound E1-1.5B')
Affinity DataIC50: 9.60nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617021(US11752155, Compound E1-1.5B')
Affinity DataIC50: 9.60nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617039(US11752155, Compound E1-24.4B')
Affinity DataKi:  10nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617013(US11752155, Compound E1-2.2B')
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617013(US11752155, Compound E1-2.2B')
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617013(US11752155, Compound E1-2.2B')
Affinity DataIC50: 10.4nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 11nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 11nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388301(US10294230, Compound E1-22.2 | US10584127, Compoun...)
Affinity DataIC50: 11nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM617029(US11752155, Compound E1-21.33B')
Affinity DataKi:  11nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Rat)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM435145(US10584127, Compound E1-9.2 | US11136328, Compound...)
Affinity DataKi:  11.3nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 13.9nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 13.9nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388302(US10294230, Compound E1-21.2 | US10584127, Compoun...)
Affinity DataIC50: 13.9nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM388299(US10294230, Compound E1-1.3 | US10584127, Compound...)
Affinity DataIC50: 14.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
US Patent

Displayed 1 to 50 (of 151 total ) | Next | Last >>
Jump to: